Jia Jenny Liu, Translational Lead of Early Phase Drug Development at The Kinghorn Cancer Centre, shared a post on LinkedIn:
“What does it really take to make early phase cancer clinical trials smarter?
For me, this conversation gets to the heart of where cancer care needs to go next.
Genomic testing, biomarkers and clinical trials matter, but they only change outcomes if we build systems that help the right patient reach the right trial at the right time.
That means better navigation, better collaboration, thoughtful toxicity management, and genuine partnership with patients and advocates.
Beth Ivimey OAM brings an extraordinary perspective through her lived experience, clinical background and advocacy. Her voice is a powerful reminder that smarter cancer care is not just about scientific innovation. It is also about compassion, clarity, access and designing systems around the people they are meant to serve.
This is an important conversation for clinicians, industry partners and scientific collaborators, because smarter drug development is not just about molecules, biomarkers or trial design – it is about patients.
And as new treatment classes such as antibody-drug conjugates move rapidly through clinical development, the next step will be smarter, more efficient patient selection using the right biomarkers.
Thank you to Beth Ivimey OAM, Rachael Babin, and The Oncology Network for creating space for this conversation.
Podcast.”
Other articles about Precision Oncology on OncoDaily.